ArticleJournal of pharmaceutical health care and sciences2025
A case of hepatitis B virus reactivation after elranatamab therapy in a patient with multiple myeloma.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA).Clinical and molecular hepatology · 2026Article
- Article
- Bispecific Antibodies: Strategies Available to Optimize Their Safe Delivery in Patients with Multiple Myeloma.Antibodies (Basel, Switzerland) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple myeloma is an incurable hematologic malignancy. Although novel treatments have improved outcomes, many patients continue to relapse and eventually develop treatment resistance. Elranatamab, a bispecific antibody, has demonstrated promising efficacy in patients with relapsed/refractory multiple myeloma. However, clinical experience with elranatamab remains limited, and its immunomodulatory effects may increase the risk of opportunistic infections and viral reactivation. Here, we describe hepatitis B virus (HBV) reactivation in a patient with resolved HBV infection who was treated with elranatamab. CASE PRESENTATION: A 76-year-old man with resolved HBV infection and treatment-resistant multiple myeloma received elranatamab. HBV DNA was not detected prior to treatment. On day 17 after initiation, an outpatient specimen returned as detectable but below the assay's lower limit of quantification (< 1.0 log10 IU/mL). Elranatamab was discontinued due to hypotension, and the patient was subsequently hospitalized one week later with pneumonia. On day 78 after initiation, HBV DNA increased to 3.6 log10 IU/mL with transaminase elevation; tenofovir alafenamide 25 mg once daily was started the same day, after which HBV DNA declined to below the lower limit of quantification.
conclusionsAlthough elranatamab-specific information on HBV reactivation is limited, this case highlights a clinically relevant risk. Clinicians should remain vigilant for reactivation in patients receiving elranatamab, particularly those with resolved infection. Regular HBV DNA monitoring and prompt initiation of nucleos(t)ide analog therapy are essential to prevent severe complications, including fulminant hepatitis. Additionally, in the context of profound hypogammaglobulinemia during or after elranatamab, intravenous immunoglobulin may be considered to mitigate infection risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.